Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anagrelide CR in MPN-related Thrombocytosis
NCT02125318Phase 2
Key facts
- Status
- Completed
- Start
- May 2014
- Primary completion
- May 2016
- Countries
- 1
- Sponsor
- Galena Biopharma
- Modality
- Small Molecules
- Drugs
- anagrelide
- Conditions
- thrombocytosis
01
Overview
Phase 2, open-label, single-arm trial of anagrelide in thrombocytosis, sponsored by Galena Biopharma. Primary endpoint: Proportion of subjects who achieve a platelet response (CR or PR) at 24 weeks. Started May 2014; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Anagrelide CR
Anagrelide Controlled Release (GALE-401)
03
Who it enrols
Adult patients with MPN-related thrombocytosis (platelets >= 600 x 10^9/L) who require platelet reduction therapy and are not refractory to anagrelide.
04
Endpoints
Primary
Proportion of subjects who achieve a platelet response (CR or PR)
Secondary
Number of subjects with adverse events
Plasma concentrations of anagrelide
Beyond the preview
Go deeper on NCT02125318.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02125318.